$REGN REGENERON PHARMACEUTICALS, INC. Insider Trading Week 13/2020
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in REGENERON PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in REGENERON PHARMACEUTICALS, INC. in week 13/2020.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 3,000 | 818,100 | 45,500 | |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 1,500 | 409,050 | 48,500 | |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 2,000 | 545,400 | 50,000 | |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 2,500 | 681,750 | 52,000 | |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 499.37 | 73 | 36,454 | 24,373 | 24.4 K to 24.4 K (-0.30 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 3,000 | 818,100 | 45,500 | |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 498.80 | 62 | 30,926 | 24,446 | 24.5 K to 24.4 K (-0.25 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 1,500 | 409,050 | 48,500 | |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 497.60 | 25 | 12,440 | 24,508 | 24.5 K to 24.5 K (-0.10 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 2,000 | 545,400 | 50,000 | |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 496.33 | 54 | 26,802 | 24,533 | 24.6 K to 24.5 K (-0.22 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | M | 272.70 | 2,500 | 681,750 | 52,000 | |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 495.56 | 2 | 991 | 24,587 | 24.6 K to 24.6 K (-0.01 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 499.37 | 73 | 36,454 | 24,373 | 24.4 K to 24.4 K (-0.30 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 494.42 | 172 | 85,040 | 24,589 | 24.8 K to 24.6 K (-0.69 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 498.80 | 62 | 30,926 | 24,446 | 24.5 K to 24.4 K (-0.25 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 493.51 | 99 | 48,857 | 24,761 | 24.9 K to 24.8 K (-0.40 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 497.60 | 25 | 12,440 | 24,508 | 24.5 K to 24.5 K (-0.10 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 492.76 | 25 | 12,319 | 24,860 | 24.9 K to 24.9 K (-0.10 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 496.33 | 54 | 26,802 | 24,533 | 24.6 K to 24.5 K (-0.22 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 490.66 | 50 | 24,533 | 24,885 | 24.9 K to 24.9 K (-0.20 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 495.56 | 2 | 991 | 24,587 | 24.6 K to 24.6 K (-0.01 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 489.50 | 121 | 59,230 | 24,935 | 25.1 K to 24.9 K (-0.48 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 494.42 | 172 | 85,040 | 24,589 | 24.8 K to 24.6 K (-0.69 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 497.48 | 25 | 12,437 | 25,056 | 25.1 K to 25.1 K (-0.10 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 493.51 | 99 | 48,857 | 24,761 | 24.9 K to 24.8 K (-0.40 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 496.28 | 11 | 5,459 | 25,081 | 25.1 K to 25.1 K (-0.04 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 492.76 | 25 | 12,319 | 24,860 | 24.9 K to 24.9 K (-0.10 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 495.24 | 69 | 34,172 | 25,092 | 25.2 K to 25.1 K (-0.27 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 490.66 | 50 | 24,533 | 24,885 | 24.9 K to 24.9 K (-0.20 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 489.50 | 121 | 59,230 | 24,935 | 25.1 K to 24.9 K (-0.48 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 497.48 | 25 | 12,437 | 25,056 | 25.1 K to 25.1 K (-0.10 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 496.28 | 11 | 5,459 | 25,081 | 25.1 K to 25.1 K (-0.04 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 495.24 | 69 | 34,172 | 25,092 | 25.2 K to 25.1 K (-0.27 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 494.68 | 91 | 45,016 | 25,161 | 25.3 K to 25.2 K (-0.36 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 493.54 | 146 | 72,057 | 25,252 | 25.4 K to 25.3 K (-0.57 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 492.60 | 109 | 53,693 | 25,398 | 25.5 K to 25.4 K (-0.43 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 491.72 | 85 | 41,796 | 25,507 | 25.6 K to 25.5 K (-0.33 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 490.11 | 51 | 24,996 | 25,592 | 25.6 K to 25.6 K (-0.20 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 489.39 | 128 | 62,642 | 25,643 | 25.8 K to 25.6 K (-0.50 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 488.55 | 246 | 120,183 | 25,771 | 26 K to 25.8 K (-0.95 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 494.68 | 91 | 45,016 | 25,161 | 25.3 K to 25.2 K (-0.36 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 487.29 | 91 | 44,343 | 26,017 | 26.1 K to 26 K (-0.35 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 493.54 | 146 | 72,057 | 25,252 | 25.4 K to 25.3 K (-0.57 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 486.66 | 78 | 37,959 | 26,108 | 26.2 K to 26.1 K (-0.30 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 492.60 | 109 | 53,693 | 25,398 | 25.5 K to 25.4 K (-0.43 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 485.63 | 62 | 30,109 | 26,186 | 26.2 K to 26.2 K (-0.24 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 491.72 | 85 | 41,796 | 25,507 | 25.6 K to 25.5 K (-0.33 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 484.96 | 22 | 10,669 | 26,248 | 26.3 K to 26.2 K (-0.08 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 490.11 | 51 | 24,996 | 25,592 | 25.6 K to 25.6 K (-0.20 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 483.51 | 139 | 67,208 | 26,270 | 26.4 K to 26.3 K (-0.53 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 489.39 | 128 | 62,642 | 25,643 | 25.8 K to 25.6 K (-0.50 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 492.05 | 2,317 | 1,140,080 | 26,409 | 28.7 K to 26.4 K (-8.07 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 488.55 | 246 | 120,183 | 25,771 | 26 K to 25.8 K (-0.95 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 3,000 | 818,100 | 28,726 | 25.7 K to 28.7 K (+11.66 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 487.29 | 91 | 44,343 | 26,017 | 26.1 K to 26 K (-0.35 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 488.20 | 1,162 | 567,288 | 25,726 | 26.9 K to 25.7 K (-4.32 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 486.66 | 78 | 37,959 | 26,108 | 26.2 K to 26.1 K (-0.30 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 1,500 | 409,050 | 26,888 | 25.4 K to 26.9 K (+5.91 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 485.63 | 62 | 30,109 | 26,186 | 26.2 K to 26.2 K (-0.24 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 488.22 | 1,549 | 756,253 | 25,388 | 26.9 K to 25.4 K (-5.75 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 484.96 | 22 | 10,669 | 26,248 | 26.3 K to 26.2 K (-0.08 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 2,000 | 545,400 | 26,937 | 24.9 K to 26.9 K (+8.02 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 483.51 | 139 | 67,208 | 26,270 | 26.4 K to 26.3 K (-0.53 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 488.22 | 1,936 | 945,194 | 24,937 | 26.9 K to 24.9 K (-7.20 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 492.05 | 2,317 | 1,140,080 | 26,409 | 28.7 K to 26.4 K (-8.07 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 2,500 | 681,750 | 26,873 | 24.4 K to 26.9 K (+10.26 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 3,000 | 818,100 | 28,726 | 25.7 K to 28.7 K (+11.66 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 493.08 | 156 | 76,920 | 24,373 | 24.5 K to 24.4 K (-0.64 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 488.20 | 1,162 | 567,288 | 25,726 | 26.9 K to 25.7 K (-4.32 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 492.61 | 64 | 31,527 | 24,529 | 24.6 K to 24.5 K (-0.26 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 1,500 | 409,050 | 26,888 | 25.4 K to 26.9 K (+5.91 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 490.70 | 87 | 42,691 | 24,593 | 24.7 K to 24.6 K (-0.35 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 488.22 | 1,549 | 756,253 | 25,388 | 26.9 K to 25.4 K (-5.75 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 489.46 | 61 | 29,857 | 24,680 | 24.7 K to 24.7 K (-0.25 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 2,000 | 545,400 | 26,937 | 24.9 K to 26.9 K (+8.02 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 488.77 | 23 | 11,242 | 24,741 | 24.8 K to 24.7 K (-0.09 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Payment of Exercise | F | 488.22 | 1,936 | 945,194 | 24,937 | 26.9 K to 24.9 K (-7.20 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 486.27 | 23 | 11,184 | 24,764 | 24.8 K to 24.8 K (-0.09 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Buy | M | 272.70 | 2,500 | 681,750 | 26,873 | 24.4 K to 26.9 K (+10.26 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 484.14 | 1 | 484 | 24,787 | 24.8 K to 24.8 K (0.00 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 493.08 | 156 | 76,920 | 24,373 | 24.5 K to 24.4 K (-0.64 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 481.91 | 87 | 41,926 | 24,788 | 24.9 K to 24.8 K (-0.35 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 492.61 | 64 | 31,527 | 24,529 | 24.6 K to 24.5 K (-0.26 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 479.50 | 75 | 35,963 | 24,875 | 25 K to 24.9 K (-0.30 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 490.70 | 87 | 42,691 | 24,593 | 24.7 K to 24.6 K (-0.35 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 478.97 | 23 | 11,016 | 24,950 | 25 K to 25 K (-0.09 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 489.46 | 61 | 29,857 | 24,680 | 24.7 K to 24.7 K (-0.25 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 488.77 | 23 | 11,242 | 24,741 | 24.8 K to 24.7 K (-0.09 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 486.27 | 23 | 11,184 | 24,764 | 24.8 K to 24.8 K (-0.09 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 484.14 | 1 | 484 | 24,787 | 24.8 K to 24.8 K (0.00 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 481.91 | 87 | 41,926 | 24,788 | 24.9 K to 24.8 K (-0.35 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 479.50 | 75 | 35,963 | 24,875 | 25 K to 24.9 K (-0.30 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Sell | S | 478.97 | 23 | 11,016 | 24,950 | 25 K to 25 K (-0.09 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Option Exercise | M | 59.20 | 5,000 | 296,000 | 39,933 | |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Option Exercise | M | 59.20 | 5,000 | 296,000 | 44,933 | |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Option Exercise | M | 59.20 | 5,000 | 296,000 | 49,933 | |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 497.32 | 100 | 49,732 | 14,438 | 14.5 K to 14.4 K (-0.69 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 496.50 | 210 | 104,265 | 14,538 | 14.7 K to 14.5 K (-1.42 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 495.19 | 321 | 158,956 | 14,748 | 15.1 K to 14.7 K (-2.13 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 494.36 | 111 | 54,874 | 15,069 | 15.2 K to 15.1 K (-0.73 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 493.35 | 652 | 321,664 | 15,180 | 15.8 K to 15.2 K (-4.12 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 492.62 | 521 | 256,655 | 15,832 | 16.4 K to 15.8 K (-3.19 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 491.42 | 450 | 221,139 | 16,353 | 16.8 K to 16.4 K (-2.68 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 490.32 | 484 | 237,315 | 16,803 | 17.3 K to 16.8 K (-2.80 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 489.72 | 734 | 359,454 | 17,287 | 18 K to 17.3 K (-4.07 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 488.26 | 1,626 | 793,911 | 18,021 | 19.6 K to 18 K (-8.28 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 487.71 | 470 | 229,224 | 19,647 | 20.1 K to 19.6 K (-2.34 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 486.61 | 485 | 236,006 | 20,117 | 20.6 K to 20.1 K (-2.35 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 485.65 | 441 | 214,172 | 20,602 | 21 K to 20.6 K (-2.10 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Sell | S | 484.58 | 192 | 93,039 | 21,043 | 21.2 K to 21 K (-0.90 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Payment of Exercise | F | 488.22 | 2,689 | 1,312,824 | 21,235 | 23.9 K to 21.2 K (-11.24 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Buy | M | 59.20 | 5,000 | 296,000 | 23,924 | 18.9 K to 23.9 K (+26.42 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Payment of Exercise | F | 488.22 | 2,757 | 1,346,023 | 18,924 | 21.7 K to 18.9 K (-12.72 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Buy | M | 59.20 | 5,000 | 296,000 | 21,681 | 16.7 K to 21.7 K (+29.97 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Payment of Exercise | F | 488.22 | 2,757 | 1,346,023 | 16,681 | 19.4 K to 16.7 K (-14.18 %) |
| Apr 03 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Buy | M | 59.20 | 5,000 | 296,000 | 19,438 | 14.4 K to 19.4 K (+34.63 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 495.66 | 1 | 496 | 28,943 | 28.9 K to 28.9 K (0.00 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 493.35 | 1 | 493 | 28,944 | 28.9 K to 28.9 K (0.00 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 492.71 | 3 | 1,478 | 28,945 | 28.9 K to 28.9 K (-0.01 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 491.13 | 2 | 982 | 28,948 | 29 K to 28.9 K (-0.01 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 490.35 | 1 | 490 | 28,950 | 29 K to 29 K (0.00 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 489.56 | 5 | 2,448 | 28,951 | 29 K to 29 K (-0.02 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 488.62 | 10 | 4,886 | 28,956 | 29 K to 29 K (-0.03 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 487.54 | 1 | 488 | 28,966 | 29 K to 29 K (0.00 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 486.53 | 4 | 1,946 | 28,967 | 29 K to 29 K (-0.01 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 485.65 | 3 | 1,457 | 28,971 | 29 K to 29 K (-0.01 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 484.54 | 8 | 3,876 | 28,974 | 29 K to 29 K (-0.03 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 483.49 | 11 | 5,318 | 28,982 | 29 K to 29 K (-0.04 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 482.43 | 14 | 6,754 | 28,993 | 29 K to 29 K (-0.05 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 481.34 | 4 | 1,925 | 29,007 | 29 K to 29 K (-0.01 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 480.55 | 8 | 3,844 | 29,011 | 29 K to 29 K (-0.03 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 479.60 | 18 | 8,633 | 29,019 | 29 K to 29 K (-0.06 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 478.45 | 4 | 1,914 | 29,037 | 29 K to 29 K (-0.01 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 477.58 | 2 | 955 | 29,041 | 29 K to 29 K (-0.01 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 469.49 | 4 | 1,878 | 29,043 | 29 K to 29 K (-0.01 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 468.14 | 24 | 11,235 | 29,047 | 29.1 K to 29 K (-0.08 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 467.51 | 19 | 8,883 | 29,071 | 29.1 K to 29.1 K (-0.07 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 466.60 | 23 | 10,732 | 29,090 | 29.1 K to 29.1 K (-0.08 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 465.35 | 16 | 7,446 | 29,113 | 29.1 K to 29.1 K (-0.05 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 464.49 | 9 | 4,180 | 29,129 | 29.1 K to 29.1 K (-0.03 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 463.16 | 3 | 1,389 | 29,138 | 29.1 K to 29.1 K (-0.01 %) |
| Apr 01 2020 | REGN | REGENERON PHARMACE ... | RYAN ARTHUR F | Director | Sell | S | 462.80 | 2 | 926 | 29,141 | 29.1 K to 29.1 K (-0.01 %) |